170 related articles for article (PubMed ID: 35984893)
1. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells.
Delfanti G; Cortesi F; Perini A; Antonini G; Azzimonti L; de Lalla C; Garavaglia C; Squadrito ML; Fedeli M; Consonni M; Sesana S; Re F; Shen H; Dellabona P; Casorati G
Sci Immunol; 2022 Aug; 7(74):eabn6563. PubMed ID: 35984893
[TBL] [Abstract][Full Text] [Related]
2. Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.
Wolf BJ; Choi JE; Exley MA
Front Immunol; 2018; 9():384. PubMed ID: 29559971
[TBL] [Abstract][Full Text] [Related]
3. Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.
Delfanti G; Dellabona P; Casorati G; Fedeli M
Front Med (Lausanne); 2022; 9():897750. PubMed ID: 35615083
[TBL] [Abstract][Full Text] [Related]
4. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
[TBL] [Abstract][Full Text] [Related]
5. Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner.
Takami M; Aoki T; Nishimura K; Tanaka H; Onodera A; Motohashi S
Cancer Res Commun; 2024 Feb; 4(2):446-459. PubMed ID: 38319156
[TBL] [Abstract][Full Text] [Related]
6. Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.
Zhu Y; Smith DJ; Zhou Y; Li YR; Yu J; Lee D; Wang YC; Di Biase S; Wang X; Hardoy C; Ku J; Tsao T; Lin LJ; Pham AT; Moon H; McLaughlin J; Cheng D; Hollis RP; Campo-Fernandez B; Urbinati F; Wei L; Pang L; Rezek V; Berent-Maoz B; Macabali MH; Gjertson D; Wang X; Galic Z; Kitchen SG; An DS; Hu-Lieskovan S; Kaplan-Lefko PJ; De Oliveira SN; Seet CS; Larson SM; Forman SJ; Heath JR; Zack JA; Crooks GM; Radu CG; Ribas A; Kohn DB; Witte ON; Yang L
Cell Stem Cell; 2019 Oct; 25(4):542-557.e9. PubMed ID: 31495780
[TBL] [Abstract][Full Text] [Related]
7. iNKT cell cytotoxic responses control T-lymphoma growth in vitro and in vivo .
Bassiri H; Das R; Guan P; Barrett DM; Brennan PJ; Banerjee PP; Wiener SJ; Orange JS; Brenner MB; Grupp SA; Nichols KE
Cancer Immunol Res; 2014 Jan; 2(1):59-69. PubMed ID: 24563871
[TBL] [Abstract][Full Text] [Related]
8. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T
J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390
[TBL] [Abstract][Full Text] [Related]
9. Primary Mouse Invariant Natural Killer T (iNKT) Cell Purification and Transduction.
Delfanti G; Dellabona P; Casorati G
Bio Protoc; 2023 Jul; 13(13):e4707. PubMed ID: 37449036
[TBL] [Abstract][Full Text] [Related]
10. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
11. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
Takami M; Ihara F; Motohashi S
Front Immunol; 2018; 9():2021. PubMed ID: 30245690
[TBL] [Abstract][Full Text] [Related]
12. Methods for Studying Mouse and Human Invariant Natural Killer T Cells.
Zhou Y; Li YR; Zeng S; Yang L
Methods Mol Biol; 2021; 2388():35-57. PubMed ID: 34524660
[TBL] [Abstract][Full Text] [Related]
13. Dissociated expression of natural killer 1.1 and T-cell receptor by invariant natural killer T cells after interleukin-12 receptor and T-cell receptor signalling.
Emoto M; Shimizu T; Koike H; Yoshizawa I; Hurwitz R; Kaufmann SH; Emoto Y
Immunology; 2010 Jan; 129(1):62-74. PubMed ID: 20028429
[TBL] [Abstract][Full Text] [Related]
14. Antitumor impact of interferon-γ producing CD1d-restricted NKT cells in murine malignant mesothelioma.
Tagawa T; Wu L; Anraku M; Yun Z; Rey-McIntyre K; de Perrot M
J Immunother; 2013 Oct; 36(8):391-9. PubMed ID: 23994885
[TBL] [Abstract][Full Text] [Related]
15. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
16. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
17. Development of genetically engineered iNKT cells expressing TCRs specific for the M. tuberculosis 38-kDa antigen.
Jiang ZM; Luo W; Wen Q; Liu SD; Hao PP; Zhou CY; Zhou MQ; Ma L
J Transl Med; 2015 May; 13():141. PubMed ID: 25943357
[TBL] [Abstract][Full Text] [Related]
18. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
19. Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen.
Sprengers D; Sillé FC; Derkow K; Besra GS; Janssen HL; Schott E; Boes M
Gastroenterology; 2008 Jun; 134(7):2132-43. PubMed ID: 18549881
[TBL] [Abstract][Full Text] [Related]
20. Novel in vitro invariant natural killer T cell functional assays.
Balasko A; Graydon C; Fowke KR
J Immunol Methods; 2021 Dec; 499():113171. PubMed ID: 34706265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
